Home
Learn More
Release Features
Success Stories
Contact Us
Search Archives
PRWeb Direct
Submit Release
July 5, 2008
 
Industry Categories  
News by Country  
News by MSA  
Todays News  
Browse by Day  
PR Trackbacks™  
Featured Videos  
ViewNews™  
eBook Digests  
RSS  
 
PRWeb, a leader in online news and press release distribution, has been used by more than 40,000 organizations of all sizes to increase the visibility of their news, improve their search engine rankings and drive traffic to their Web site.
 
All Press Releases for February 17, 2005 Subscribe to this News Feed      
 

Could This Mean an End to Cataract Surgery?

A spokesman for http://www.cataract-clear.ch said "Everyone is extremely pleased with the results of this revolutionary new treatment. It's nice to be able to offer a successful alternative to invasive surgery. The majority of people using Bright Eyes are seeing positive results over a 3-6 month period".

(PRWEB) February 17, 2005 -- Cataract-Clear.ch is providing a revolutionary new treatment for cataracts called "Bright Eyes". The Swiss manufacturers claim "This could be an end to cataract surgery". A spokesman for Cataract-Clear.ch said that 17 million people around the world are blind because of cataracts and 28,000 new cases are reported every day. In the U.K. alone, just one London hospital carries out between 250 and 500 cataract operations every week and, at any one time, 500,000 people are awaiting cataract surgery, or paying out considerable sums for private treatment.

The product Bright Eyes uses a special derivative of the naturally occurring neuropeptide L-Carnosine, called N-Acetyl-Carnosine (NAC), which is a super antioxidant and anti-glycating agent. NAC, when topically applied, can penetrate and protect the lipid tissues of the eye against light damage. It also helps to diminish free radical damage and the harmful effects of glycosylation associated with degenerative eye disease. Professor Steven Charles Gallant, the world renowned biochemist who was originally responsible for introducing Bright Eyes to Europe says; I have been studying the effects of L-Carnosine for many years. It was first discovered back in 1988 that N-Acetyl-Carnosine had positive effects on cataracts. My father had cataracts and did not relish going under the knife so I tried to get some for him but unfortunately, at the time, it wasnt easily obtainable. My father had to have the operation, which thankfully was successful. But that got me to thinking how great it would be if we were to develop, and make readily available, a product whereby this condition could be addressed with a simple course of eye drops as opposed to surgery. After many years research, development and trials of Bright Eyes, many people are now enjoying much-improved vision due to this exciting medical breakthrough."

###

Technorati Tags

Bookmark -  Del.icio.us | Digg | Furl It | Spurl | RawSugar | Simpy | Shadows | Blink It | My Web



OPTIONS
Printer Friendly Version
Download PDF Version
Download Reader Version
Email this story to a colleague
CONTACT INFORMATION
Simon Howlett
Ethos GmbH Schweiz
41-71-669-1440
Email us Here
ATTACHED FILES

There are no multimedia files attached to this release. If this is your release, you may add images or other multimedia files through your login.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these releases. Our complete disclaimer appears here.
 
Disclaimer: If you have any questions regarding information in these press releases please contact the company listed in the press release.
Please do not contact PRWeb®. We will be unable to assist you with your inquiry.
PRWeb® disclaims any content contained in these releases. Our complete disclaimer appears here.

© Copyright 1997-2008, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Terms of Service | Privacy Policy | Copyright